AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT) Files An 8-K Results of Operations and Financial Condition


AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Conditions.

On March 12, 2018, Aimmune Therapeutics, Inc. (“Aimmune” or the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2017, and its financial position as of December 31, 2017. The full text of the press release is furnished as Exhibit 99.1 hereto.

The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, or incorporated by reference into any filings of the Company made under the Securities Act of 1933, as amended, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 9.01 Financial Statements and Exhibits.




Press release dated March 12, 2018.

Aimmune Therapeutics, Inc. Exhibit
EX-99.1 2 aimt-ex991_7.htm EX-99.1 aimt-ex991_7.htm Exhibit 99.1 Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results     • Company began 2018 with approximately $182 Million in cash and investments   • Pro-forma year-end 2017 cash and investments of approximately $372 Million,…
To view the full exhibit click here


Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation. For patients in the up-dosing phase of the AR101 treatment regimen, AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels.

An ad to help with our costs